Larger consumer health firms are “looking to move-the-needle opportunities, which are big brands, big categories, different regions than we compete in as part of their business objective,” says CEO Ron Lombardi as PCH reports revenues down slightly from year-ago period at $286.3m.

Consumer health products sector’s earnings reports for July-September period are its first since FDA advisory committee unanimously voted that results of research agency presented show oral phenylephrine at OTC monograph doses is ineffective to treat nasal congestion.

Beauty and consumer health care weren’t among the the consumer packaged goods categories showing private label market-share growth during April-June period. Consumer health industry executives see more spending on private label in some categories but without affecting their results.

Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.